Squarepoint’s Soleno Therapeutics SLNO Stock Holding History

Squarepoint’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,500	Closed	-$893K	–	5005
2025 Q1	$893K	Buy	12,500 +6,600	+112%	+$321K	﹤0.01%	2777
2024 Q4	$265K	Sell	5,900 -1,600	-21%	-$82.9K	﹤0.01%	4247
2024 Q3	$379K	Buy	+7,500	New	+$359K	﹤0.01%	3308

Squarepoint's SLNO Position: Q2 2026 in Review

Squarepoint sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 185,337 shares — an estimated $6.21M sold.

Squarepoint first reported a position in SLNO in Q1 2020 and held it in 9 quarters. The position peaked at $21.7M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Squarepoint reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 185,337 Soleno Therapeutics shares in Q2 2026, an estimated $6.21M.
Squarepoint first reported a position in Soleno Therapeutics in Q1 2020 and held it in 9 quarters.
Squarepoint's Soleno Therapeutics position peaked at $21.7M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.